Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dat' all you got!! HA!! HA!! EOM
IW2B Hopefully, I will be guzzling from the TAPS on my way to the Carribbean. Good Luck
HAA! HAA! EXTRA GREEN TONITE!! EOM
Niko, notice the 80,000,000 shares traded in December in conjuction with that article.
Dr., I agree. I don't like dirty business. But...sometimes you gotta throw somebody under the truck. Good Luck
niko,
This is the latest on statinome. Interesting that article hasn't been published yet. Good Luck
December 19, 2006 - 7:00 AM EST
DNAPrint Announces Discovery of Genetic Marker for Statin-Induced Myalgia
Findings From Company's Statnome Project Successfully Validated; Article on Study to Be Published in Noted Academic Journal
DNAPrint Genomics, Inc. (OTCBB: DNAG), today announced that the Company's research staff has discovered a genetic marker for statin-induced myalgia (chronic muscle pain), that a patent has been filed to protect the discovery and that the research on which the discovery is based will be published in an upcoming issue of The Journal of Pharmacogenetics and Genomics (JPG).
The marker was the primary discovery from the Company's Statnome project initiated in 2000 and the manuscript to be published in JPG describes the validation of this finding in different patient samples.
"Myalgia or chronic muscle pain is a common side effect reported by patients who take statins for cholesterol control, and it is likely to be part of a disease continuum that includes myositis and rhabdomyolysis, which is a breakdown of muscle fibers that frequently results in kidney damage and is a potentially fatal side-effect," according to DNAPrint Chief Science Officer Tony Frudakis, Ph.D. "Deaths associated with statin-induced rhabdoymyolysis lead Bayer to withdraw Cerivistatin in 2001. We are satisfied to have brought one of our first pharmacogenetics programs full circle from discovery through validation and we consider the R&D phase for this project complete. With the filing of a patent to protect this discovery, the Company will be able to develop a proprietary test for this gene variant and thereby reduce the likelihood of illness or death in those patients who are taking statins. This study also criticizes the original clinical trials for statins, which did not fully or adequately explore the relationship between statins and myalgia or even rhabdomyolysis."
"This is the culmination of a project that was begun when the company was founded," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "It has taken until now to validate the original findings, but validated they are. The Company has filed a patent to protect this process. We plan to bring to market a definitive test product to identify this genetic variant and to potentially prevent painful -- and in some cases, fatal -- side effects in thousands of patients who are taking a very common prescription drug."
DNAPrint's study of 750 patients who had taken either atorvastatin (Lipitor®) or simvastatin (Zocor®) showed that patients carrying one specific genetic marker were approximately 2.5 times more likely to experience mild to severe muscle pain (myalgia). The effect was most pronounced for atorvastatin and the study showed that approximately one half of the patients who were removed from atorvastatin therapy due to muscle symptoms possess this genetic marker, whereas in the general population (with and without cardiovascular disease) only approximately 15%-25% of people carry the marker. DNAPrint applied its technology for measuring population structure (e.g., ancestry) in order to prove that the finding in both the discovery and validation samples was genuine, and in so doing received praise from JPG reviewers. This observation indicates that the genetic marker may be related not only to response to statins but also to a possible relationship with higher cholesterol levels, according to the study.
"DNA Print Genomics was founded on the underlying genomic screening methods developed to more efficiently scan the genome for medically important genetic markers of drug responses," stated Dr. Frudakis. "The current findings are another example of the efficiency of the Company's methods."
Dr., A small amount to pay for the Talent we received. As a shareholder I am entirely comfortable, and as a businessman appreciative with the conduct of our Directors.
Frog's are not supposed to JUMP IN the muskrat trap. Gabriel and Gomez cut Bookbinder out. PLAIN and SIMPLE. That's business. SO WHAT...
N'JOY!!!
GENBIOMICS, LLC
Investments for Pharmaceutical Research
________________________________________________________________________________
CONSULTANT AGREEMENT
THIS CONSULTANT AGREEMENT (the Agreement), is entered into effective as of
Friday, 17 May 2002 (the Effective Date) by and between DNAPrint Genomics, Inc.,
doing business at: DNAPrint Genomics, Inc. 900 Coconut Ave., Sarasota, FL. 34236
(herein referred to as "Client") and GenBiomics, LLC with offices at 505
Paradise Rd., #281, Swampscott, MA 01907 (herein referred to as "Consultant").
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=1966117&Type=HTML
Fog, you're not gonna go underwater after the partnership is announced...are you?
Frog, you're not the only one playing tricks around here.
I'm very pleased with our management. Next question...
Bookbinder claims that the defendants essentially tricked Bookbinder into doing more than a thousand hours of consulting work for DNAPrint without compensating him properly as promised
http://www.s2report.com/reports/072005/07122005.html
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth, as of September 7, 2006 certain information concerning beneficial ownership of shares of our stock and the approximate percentage of shares of our stock owned by (i) each person known to us to own 5% or more of the outstanding shares of stock, (ii) each director and executive officer, and (iii) all directors and executive officers as a group.
11
--------------------------------------------------------------------------------
Name And Address Of Amount Of Percentage Of
Beneficial Owner(1) Beneficial Ownership Class (2)
------------------- -------------------- -------------
Tony Frudakis 21,562,829(3) 5.11%
Richard Gabriel 23,000,000(4) 5.42%
Hector Gomez 19,886,000(5) 4.71%
Directors and Officers
as a Group (3 persons) 64,448,829 13.97%
By the way foggy, I got bored splitting warts with you over the directors of this company being indemnified. You obviously don't deal with lawyers much.
Why don't you sink those green gums into something juicy like this: Please don't make me do your job for you.
We continue to fund our operations and research and development through the notes payable proceeds we receive from Dutchess. On March 6, 2006, we issued to Dutchess a promissory note in the amount of $1,500,000 for a purchase price of $1,200,000. The note is due and payable in full on March 6, 2007. Other than the $300,000 discount inherent in the purchase price, the note is non-interest-bearing. The note will be repaid using the proceeds of each put notice delivered by us to Dutchess under the September 2004 Investment Agreement.
On April 17, 2006, we issued to Dutchess a promissory note in the amount of $1,470,000 for a purchase price of $1,175,000. The note is due and payable in full on April 17, 2007. Other than the $295,000 discount inherent in the purchase price, the note is non-interest-bearing. The note will be repaid using the proceeds of each put notice delivered by us to Dutchess under the September 2004 Investment Agreement.
On May 18, 2006, we issued to Dutchess a promissory note in the amount of $1,300,000 for a purchase price of $1,000,000. The note is due and payable in full on May 18, 2007. Other than the $300,000 discount inherent in the purchase price, the note is non-interest-bearing. The note will be repaid using the proceeds of each put notice delivered by us to Dutchess under the September 2004 Investment Agreement.
On June 30, 2006, we issued to Dutchess a promissory note in the amount of $1,495,000 for a purchase price of $1,150,000. The note is due and payable in full on June 29, 2007. Other than the $345,000 discount inherent in the purchase price, the note is non-interest-bearing. The note will be repaid using the proceeds of each put notice delivered by us to Dutchess under the September 2004 Investment Agreement
Frog, your pond has been drained:
PT-401 is more potent and longer acting drug than EPO. DNAPrint™ is developing the drug as a Theranostic product, with a genomic test for assessing patient compatibility prior to administration.
Alot of concern about the effects of EPO drug. Of course, DNAG will have a genomic test to accompany Pt-401.
What value would you place on that?
FDA Panel Scrutinizes Safetyof Anti-Anemia DrugsFile Format: PDF/Adobe Acrobat
FDA Panel Scrutinizes Safetyof Anti-Anemia Drugs. clots)—in the erythropoietin-treated. group. At the May meeting of the FDA’s. Oncologic Drugs Advisory ...
jncicancerspectrum.oxfordjournals.org/cgi/reprint/jnci;96/14/10
http://jnci.oxfordjournals.org/cgi/reprint/jnci%3b96/14/1061.pdf
Fog,
The EPO has a potential to generate $10 Billion a year. If it doesn't work it will generate $0.
"Value" is what somebody is willing to pay.
Here is what we paid:
We entered into a license agreement with Beth Israel for EPO. In exchange for the license, we agreed to make certain milestone payments linked to their progress in developing marketable products from the licensed technology. The total of payments, if all milestones are reached, is $2,150,000. The milestone payments are nonrefundable. Up to $200,000 of this amount is creditable against future royalties. In addition to the milestone payments, we must also pay Beth Israel an annual royalty of 4% of the net sales of all products developed from the licensed technology. A minimum royalty payment of $100,000 a year is due upon the commencement of commercial sales in any territory worldwide.
We entered into a consulting agreement with Dr. Arthur Sytkowski, the Director of Beth Israel, to consult on the EPO project. In exchange for the services, we will pay Dr. Sytkowski $10,000 a month, five annual incentive payments of $25,000 each, and certain milestone payments totaling $125,000 linked to our progress under the Beth Israel license in developing marketable products from the licensed EPO technology. The milestone payments will be reduced - dollar for dollar - to the extent Dr. Sytkowski receives payments from Beth Israel relating to the same milestone events under the Beth Israel license.
During late March 2006, we entered into a service agreement with KBI BioPharma for services to be provided totaling $2,840,000 of which $576,000 has been paid. KBI will provide us services for the production development of EPO.
During July 2006, we entered into a collaborative research agreement with Beth Israel to provide four researchers to us to conduct certain research work related to our EPO research. This project will cost approximately $600,000.
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=4757816&Type=HTML
At the time of this filing, the original 3 year collaboration with Moffitt had just ended. Interesting to note that all other filings detailed the relationship.
One line here, using the word instituted.
Also, (BIDMC) Beth Israel Deaconess Patents' are for us to partner?!
DNAPRINT GENOMICS INC (DNAG)
Form: 10QSB
Filing Date: 11/13/2006
In addition, we have instituted a clinical development program at the Moffitt Cancer Research Center in Tampa, Florida
During 2006 and 2007, we will also review the entire BIDMC patent estate and determine if any of the other patents available to us under the licensing agreement may be partnered, joint ventured, sublicensed or otherwise exploited to help offset the cost of Super EPO development.
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=4757816&Type=HTML
RIBBITT
What info do you have to substantiate your claim that PT-401 was a simple acquisition. I've heard you use that more than once. TIA
Dr. Frudakis stated that Beth Isreal did actually enlist Pfizer for the job of creating the "Super EPO". However, Pfizer sat on their asses (in other words, they had lots of other drugs in their pipeline and were too busy to focus on BI's needs) and thanks to a loophole Beth Isreal provided in their contract, they were able to break the contract and thanks to connections with the current CEO of DNAP, DNAP was able to secure the deal.
http://mysta3.blogspot.com/2005_06_01_archive.html
STOCCKKKYYY!!!! 150 COMPANIES WHO WANT US!!!!
WOOOOWWWWWWW!!!!
http://209.85.165.104/search?q=cache:J7dDwJ3xProJ:www.starlightcapital.com/private-equity-events/age...
MO. Not Humble.
Stocky, you're on to something there. I do remember talk of Dnaprint Pharmaceuticals going public. MO. Not Humble
Pharmacogenomics is gonna come on like a ton of bricks. MO. Not Humble.
Stock, I suspect there's more to it than just Moffitt licensing our platform. If that was it, it would have been announced already. MO. Not Humble.
stock, I suspect our platform is Affymetrix Gene Chip compatible. It better be...
H. Lee Moffitt Cancer Center & Research Institute Licenses the Rosetta Resolver Gene Expression Analysis System from Rosetta Biosoftware
Business Wire, Dec 4, 2006
http://www.findarticles.com/p/articles/mi_m0EIN/is_2006_Dec_4/ai_n16881670
Rosetta Resolver uses the Affymetrix Gene Chip
http://www.affymetrix.com/products/software/compatible/expression.affx
APPLICATION CATEGORY - SNP ANALYSIS
This set of applications provides analysis solutions for Affymetrix genotyping arrays used for genome wide linkage or association studies. Starting with SNP calls, the bi-allelic state of a given SNP is indexed against its genomic location. Comparing information regarding the pattern these SNP markers across the multiple samples and the association of these SNP with phenotypic or clinical markers, regions of the genome are identified as relevant to a given trait.
http://www.affymetrix.com/products/software/compatible/snp.affx
I say we're next. It's my opinion, and it's not humble.
Merck is on a tear
1/11/07 - Merck KgaA reports European antitrust authorities have approved acquisition of Serono
http://www.pharmacychoice.com/News/article.cfm?Article_ID=46005
Bioserve being a private company, the deal b/w them and Merck is not public. Sequenome is raising $20,000,000 as we speak. I wish DNAG could do that.
SEQUENOM INC
Form: 424B3 Filing Date: 2/9/2007
$20,000,000
SEQUENOM, INC
http://businessweek.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=4941603&Type=HTML
JMHO If they already have the framework in place for these kinds of deals, I suspect "if" we are to be involved it would look very similiar.
For Profit, Non-Public Company:
BioServe = M2Gen
Publicly traded:
SQNM = DNAG
JUST A LITTLE INTERESTING:
10-K 1 d10k.htm FORM 10-K FOR SEQUENOM, INC
Products and Applications
Our MassARRAY system provides reliable results for numerous types of DNA analysis applications including SNP genotyping and allelotyping, SNP discovery, quantitative gene expression analysis, quantitative methylation marker analysis, and oligonucleotide quality control. While the MassARRAY system is versatile, it also became a more cost-effective solution for customer needs with our 2005 launch of the iPLEX assay. The iPLEX assay is a proprietary assay, which provides for multiplexed DNA sample analysis that in turn provides cost-effectiveness by allowing the user to perform multiple sample analyses using a similar amount of reagents
As of March 15, 2006, there were 40,249,748 shares of the Registrant’s Common Stock outstanding
Recent Development
On March 27, 2006, we entered into a securities purchase agreement with three investors that provides for the sale of common stock and warrants to purchase common stock to the investors for gross proceeds to us of $30.0 million not including any proceeds from exercise of the warrants.
On March 30, 2006, we amended and restated the securities purchase agreement to add a fourth investor and increase the gross proceeds to $33.0 million not including proceeds from exercise of the warrants. Under the amended and restated securities purchase agreement, we will issue to the investors, subject to the approval of our stockholders and the satisfaction of various closing conditions, (i) an aggregate of 60,000,000 shares of our common stock and (ii) seven-year warrants to purchase an aggregate of 36,000,000 shares of our common stock at an exercise price of $0.70 per share (subject to certain antidilution protections and other adjustment provisions]
We have a history of recurring losses from operations and have an accumulated deficit of $442.6 million as of December 31, 2005. Our capital requirements to sustain operations, including research and development projects, have been and will continue to be significant. As of December 31, 2005, we had available cash and short-term investments totaling $6.0 million and working capital of $5.4 million
I took this info from their 10k from 2005
http://www.sec.gov/Archives/edgar/data/1076481/000119312506070581/d10k.htm#toc88263_10
Their stock is trading at $4. Outstanding, if diluted about 140 million.
Accumulated deficit $443 million
Compare that to DNAG #'s
price: .0175
Outstanding, if diluted about 600 million
Accumulated deficit: $38 million? I think.
SQNM chart
http://www.moqvo.com/en/bioserve__bioserve_unveils_new_dna_methylation_service_4887356.html
The reason I looked at this company is because their technology is very similiar. And also because:
BioServe Unveils New DNA Methylation Service
LAUREL, MD -- (MARKET WIRE) -- December 11, 2006 -- BioServe Biotechnologies, a leader for fast, economical processing and analyses of genomic content from biological samples, today introduced its new DNA Methylation Analysis Service using Sequenom, Inc.'s (NASDAQ: SQNM) MassARRAY® System and EpiTYPER™ methodology.
http://www.moqvo.com/en/bioserve__bioserve_unveils_new_dna_methylation_service_4887356.html
AND THIS:[/B]
BioServe Signs Distribution Deal With Merck Specialties Private Limited
LAUREL, MD -- (MARKET WIRE) -- January 09, 2007 -- BioServe Biotechnologies, the leader for fast, economical processing and analyses of genomic content from biological samples, today announced a distribution deal with Merck Specialties Private Limited (MSPL), 100% Indian subsidiary of Merck KgaA. Under terms of the contract, MSPL will market and distribute BioServe's genomic products and services, including DNA and RNA purification reagents, DNA sequencing, oligonucleotide synthesis and molecular biology teaching kits in India, with plans to extend distribution coverage across Asia in 2007.
http://www.moqvo.com/en/bioserve__bioserve_signs_distribution_deal_with_merck_specialties_private_li...
My Green Slimy Friend,
You are splitting warts. There's always an indemnification clause. Standard in contracts.
10KSB · For 12/31/05 · EX-10.33
The Company shall defend, protect, indemnify and hold harmless the Holder and all of its shareholders, officers, directors, employees, counsel, and direct or indirect investors and any of the foregoing person's agents or other representatives etc..etc..
http://209.85.165.104/search?q=cache:lJnWQtrGjW0J:www.secinfo.com/d15yrh.v64.b.htm+dnag+indemnificat...
Are you upset that Sytkowski and his associates were indemnified back in September of '05.
Form:10QSB Filing Date:11/15/2005
INDEMNIFICATION - DNAP shall indemnify, defend and hold harmless DR.
SYTKOWSKI and his employees and agents and their respective heirs, successors
and assigns (the "INDEMNITEES"), against any liability, damage, loss, or expense
(including attorneys' fees and expenses of litigation) actually incurred by or
imposed upon the INDEMNITEES or any one of them in connection with any claims,
suits, actions, demands, or judgments of any party other than DNAP arising out
of or relating to the PROJECT, including, but not limited to, any theory of
product liability (including but not limited to, strict liability) concerning
any products, process or service made, used or sold pursuant to any rights
granted under this AGREEMENT. DNAP's indemnification shall not apply to any
claim, suit, action, demand, loss or expense (including attorneys' fees and
expenses of litigation) to the extent that it is actually incurred or imposed or
is due to the breach of this AGREEMENT, violation of or failure to comply with
any law, or governmental regulation, negligence, reckless MISCONDUCT or
intentional MISCONDUCT (hereinafter collectively the " MISCONDUCT ") of any of
the INDEMNITEES.
It must be a total of 2 million shares short as the link below states around 100,000 for the day. Not 2 million each day.
DNAG $ 0.02
Dnaprint Genomics 0.00
Shares Short 100,102
Days to Cover (Short Ratio) 0.0
Short % of Float %
Shares Short - Prior 45,293
Short % Increase / Decrease 121.01 %
Squeeze Ranking™
% from 52-Wk HIGH ( 0.09 ) -400.00 %
% from 52-Wk LOW ( 0.01 ) 58.82 %
% from 200-Day MA ( 0.01 ) 41.18 %
% from 50-Day MA ( 0.01 )
41.18 %
Price % Change (52-Wk) -31.91 %
Trading Volume - Today 3,548,890
Trading Volume - Average 5,771,191
Trading Volume Vs. Avg. 61.49 %
Total Shares - Float
Total Shares - Outstanding 417,003,382
% Held by Insiders %
% Held by Institutions %
Market Cap 7,214,159
EPS -0.06
PE Ratio
Sector:
Industry:
SI Record Date 2007-Jan
Information Provided Without Warranty
http://www.shortsqueeze.com/index.php?symbol=dnag&submit=Enter
Rule 203(b)(3) generally requires any participant of a registered clearing agency to take action on all failures to deliver in threshold securities 10 days after the normal settlement date by closing out the failure to deliver by purchasing securities of like kind and quantity. In addition, until the failure to deliver is closed out, there are restrictions on further short sales in the threshold security by the participant and any broker-dealers for which it clears transactions. There is no exception in the rule for market makers.
http://www.mondaq.com/i_article.asp_Q_articleid_E_29999
We've been on 20 days.
I don't know if there is a way to find out an exact number of shares that haven't been delivered to date. Anybody?
Can't find the shares:
By Phillip Cruz
Feb. 5 (Bloomberg) -- The following is a list of ``threshold securities'' from the Nasdaq Stock Market, published daily in compliance with the U.S. Securities and Exchange Commission's Regulation SHO.
The list consists of stocks for which sellers failed to deliver 10,000 shares or more in the past five trading days and the level of ``fails'' is a minimum of 0.5 percent of the shares outstanding. Securities are listed alphabetically by ticker.
.5% is over 2 million shares for last twenty days
http://www.buyins.net/tools/short_list.php?dys=%3E12&sort=symbol&order=1&name=NakedShort...
THE lawsuit was settled. Utah state law requires they indemnify directors. RIBBITT...BURP
I'll post it again
Furthermore, Section 16-10a-903 of the Utah Revised Corporation Act mandates indemnification, and states "nless limited by its articles of incorporation, a corporation shall indemnify a director who was successful, on the merits or otherwise, in the defense of any proceeding, or in the defense of any claim, issue, or matter in the proceeding, to which he was a party because he is or was a director of the corporation, against reasonable expenses incurred by him in connection with the proceeding or claim with respect to which he has been successful." U.C.A. 1953 ss 16-10a-903
DNAPRINT GENOMICS INC (DNAG)
Form: S-8
Filing Date: 2/16/2007
AMENDMENT TO SETTLEMENT AGREEMENT AND RELEASE
This 14th day of February, 2007, Lonnie L. Bookbinder, DNAPrint Genomics, Inc. and Genbiomics, LLC, a dissolved Florida limited liability company, intending to be legally bound, hereby modify and amend the Settlement Agreement and Release previously entered into by the parties on or about September 12, 2006 and hereby agree as follows:
A. Lonnie L. Bookbinder hereby acknowledges receipt of $50,000 and 1.5 million restricted shares of DNAPrint Genomics, Inc., paid and issued in accordance with the Settlement Agreement and Release referenced above.
B. In lieu of the remaining payment due under the Settlement Agreement and Release of $65,000, Lonnie L. Bookbinder agrees to accept, and DNAPrint Genomics, Inc. agrees to pay to Lonnie L. Bookbinder, the amount of $40,000 on or before February 20, 2007 and, pursuant to an S8 filing, issue to Lonnie L. Bookbinder 2.7 million shares of DNAPrint Genomics, Inc.
C. Lonnie L. Bookbinder agrees to accept the above cash payments and stock shares in full, complete, absolute and final settlement of all claims whether known or unknown, contingent or liquidated, that he may have against all persons and entities referenced in the Release provisions of the original Settlement Agreement and Release executed by him on or about September 12, 2006. All other provisions of said Settlement Agreement and Release are specifically included herein, as if fully set forth again, and remain in full force and effect.
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=4973858&Type=HTML
Furthermore, Section 16-10a-903 of the Utah Revised Corporation Act mandates indemnification, and states "nless limited by its articles of incorporation, a corporation shall indemnify a director who was successful, on the merits or otherwise, in the defense of any proceeding, or in the defense of any claim, issue, or matter in the proceeding, to which he was a party because he is or was a director of the corporation, against reasonable expenses incurred by him in connection with the proceeding or claim with respect to which he has been successful." U.C.A. 1953 ss 16-10a-903
No...All I need is a .1/share.lol
There'ya go! Wipe off your face, pull up your pants, and get out there in centerfield.
Ice, I also lost big on the reverse. I'm down well over $100k
in this stock. I first bought in at .40c after the CYTC reverse merger, when Tony and his brother George were working out of their garage. Went through the reverse riding on hope, I feel your pain. I bought back in at .03c and watched it go to .0075. I bought more. I've gotten back to 1.4 million shares.
As investors we should have sold before the R/S...when it was announced. You know it, and so do I.
I will say this: The progress I expected to see from this company certainly didn't happen in the time frame either of us wanted.
If this deal b/w Merck and Moffitt culminating in M2Gen doesn't include Dnaprint in a substantial way I'm going to run away and not look back. They are passing out shares like candy.
I wish you the best of luck. I'd also buy some more. We will pop on the news. And if you can believe this, for the first time in this companys' history we are above the 50 SMA on the long term weekly chart...whatever that might mean here in pennyland. JMHO
You are visitor number 80509 to Kerchner's DNAPrint Test Results Log Book.
http://www.kerchner.com/cgi-kerchner/dnaprint.cgi
I read it wrong. He winds up with $90,000 and 4.2 million shares.
I certainly hope we have some crack lawyers on the job.
These patents’ treatment of race as a purportedly obvious social category in contrast to a presumedly non-obvious genetic category is particularly evident in Patent Application #20040229231 “Compositions and methods for inferring ancestry,”273 filed November 18, 2004 by Tony Frudakis of DNAPrint Genomics. DNAPrint describes itself as “a cutting edge company. We are concentrating our efforts in four distinct areas; Pharmacogenomics, Forensics, Genotyping, and Consumer Products. Our aim is to continue to research and develop novel products and services in each of these market areas and to be a leader in genomic-based technologies.”274 Frudakis is claiming a method of using ancestry informative DNA markers for inferring the ancestry of a given individual. Claim #3 specifies the ability to infer what it calls “Biogeographical ancestry.” 275 Later, in the Description section, the application defines “Biogeographical ancestry” as “the heritable component of ‘race’. . .” 276 What is striking about this particular use of race in relation to genetics is the way in which Frudakis distinguishes between social and purportedly genetic aspects of race. It is genetic race – the heritable portion – which Frudakis claims is revealed through analysis of ancestry informative markers that is marked out as a distinctive basis for the patent. And yet, while clearly that acknowledging non-heritable components do race exist, (and, indeed, necessarily must be relevant to the actual application and commercial utility of the technology), it makes no attempts to define them. Again, the implicit assumption appears to be that the asserted genetic components to race are non-obvious and/or novel, while the social aspects of race are too obvious to warrant further consideration.
http://209.85.165.104/search?q=cache:Z2mHEum8JlYJ:www.case.edu/affil/sce/Texts_2006/Invention%2520pa...
stocky, what is this? Dnaprint South Africa?
http://dnaprint.co.za/
http://co.za/